Biohaven (BHVN) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvation Bio (NUVB) has outperformed Biohaven (BHVN) over the past year, gaining 33.3% versus a loss of 29.9%. Biohaven is the larger company by market cap ($1.82 billion vs $1.76 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | NUVB |
|---|---|---|
| Share price | $12.08 | $5.00 |
| Market cap | $1.82B | $1.76B |
| 1-day change | +1.26% | +1.01% |
| YTD return | +7.00% | -44.20% |
| 1-year return | -29.89% | +33.33% |
| 5-year return | — | -47.64% |
| EPS (TTM) | $-4.62 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.90M |
| Revenue growth (YoY) | — | +698.96% |
| Net income (latest FY) | $-738.82M | $-204.63M |
| Operating margin | — | -338.72% |
| Net margin | — | -325.31% |
| 52-week high | $18.57 | $9.75 |
| 52-week low | $7.48 | $3.36 |
| Distance from 52-week high | -34.93% | -48.72% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +160.00% |
| Average volume | 2.63M | 5.65M |
| Shares outstanding | 151.04M | 350.12M |
| Employees | 274 | 305 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NUVB has outperformed BHVN by 63.2 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
BHVN vs NUVB FAQ
Which is bigger, Biohaven or Nuvation Bio?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.76B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, BHVN or NUVB?
NUVB returned +33.33% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Nuvation Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.